Hale Therapeutics
About this raise
Hale Therapeutics, with a valuation of $15 million, is raising funds on SeedInvest. The company has developed its proprietary medical vaporizer and mobile app that helps smokers quit nicotine more easily. The dual-capsule solution of Hale Therapeutics is disrupting current nicotine replacement therapies and is designed to wean people off of nicotine with minimum withdrawal symptoms gradually. Josh Israel founded Hale Therapeutics in July 2018. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1,070,000. The campaign proceeds will be used for preclinical testing, clinical trials, and GMP manufacturing setup.
Investment Overview
Not Funded: $26,500
Deal Terms
Total Commitments
- Platform
- SeedInvest
- Start Date
- 02/28/2022
- Close Date
- 07/13/2022
$25,000
$1,070,000
$1,000
Convertible Note
Early Stage
RegCF
/ RegD 506(c)
$15,000,000
20%
Company & Team
Company
- Year Founded
- 2018
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2C
- Margin
- Medium
- Capital Intensity
- Low
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $1,980,000
- VC Backed?
- Yes
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 07/13/2022 | SeedInvest | $15,000,000 | $26,500 | Convertible Note | Not Funded | RegCF / RegD 506(c) |
Founder Interview
Hale Therapeutics Founder Josh Israel Is Determined to Help Smokers Quit
Once upon a time, cigarette companies marketed their products with the promises of healing properties and the trustworthy faces of dentists, babies, and Santa Claus. Today the health consequences of smoking tobacco are well known, and most smokers want to quit. But despite modern advancements in medicine and technology, quitting success rates remain dismally low.Hale Therapeutics is on a mission to help smokers quit with a new method: smoking. The company has created a patented dual-capsule vaporizer that will gradually ease smokers off of nicotine with steps that may be familiar to them. We reached out to co-founder and CEO Josh Israel to learn about the origin of Hale Therapeutics and where the company might go from here.
Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.